Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
R Ruan, L Li, X Li, C Huang, Z Zhang, H Zhong… - Molecular Cancer, 2023 - Springer
Abstract Background Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a
crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving …
crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving …
Adoptive immunotherapy for cancer or viruses
Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the
treatment of cancer and certain chronic viral infections. The application of the principles of …
treatment of cancer and certain chronic viral infections. The application of the principles of …
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite… - Nature medicine, 2021 - nature.com
Abstract Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
CU Blank, EA Rozeman, LF Fanchi, K Sikorska… - Nature medicine, 2018 - nature.com
Abstract Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-
free survival of stage III melanoma patients,. In stage IV disease, the combination of …
free survival of stage III melanoma patients,. In stage IV disease, the combination of …
[HTML][HTML] Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses
To guide the design of immunotherapy strategies for patients with early stage lung tumors,
we developed a multiscale immune profiling strategy to map the immune landscape of early …
we developed a multiscale immune profiling strategy to map the immune landscape of early …
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels
Introduction T cells are involved in the early identification and clearance of viral infections
and also support the development of antibodies by B cells. This central role for T cells makes …
and also support the development of antibodies by B cells. This central role for T cells makes …
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
L Fong, A Hotson, JD Powderly, M Sznol, RS Heist… - Cancer discovery, 2020 - AACR
Adenosine mediates immunosuppression within the tumor microenvironment through
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Daratumumab targets CD38-expressing myeloma cells through a variety of immune-
mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell …
mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell …